HERANOVA
LIVE

Serial Number

98831068

Owner

Heranova Lifesciences Inc.

Attorney

Y. Jae Kim

First Use Date

Dec 8, 2025

Filing Date

Oct 31, 2024

Add to watchlist:

No watchlists yet
View on USPTO

HERANOVA Trademark

Serial Number: 98831068 • Registration: 8357775

HERANOVA is a trademark filed by Heranova Lifesciences Inc. on October 31, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Heranova Lifesciences Inc.

2 Burlington Woods Drive, Suite 100
Burlington, MA 01803

Entity Type: 03

Trademark Details

Filing Date

October 31, 2024

Registration Date

July 21, 2026

First Use Anywhere

December 8, 2025

First Use in Commerce

December 8, 2025

Published for Opposition

July 8, 2025

Goods & Services

Providing medical information in the field of gynecology; medical information services in the gynecological field; medical testing services for diagnostic purposes in the field of gynecology, namely, testing services for detecting endometritis, a woman's personalized embryo implantation time, and/or Pelvic Inflammatory Disease and antibiotic resistance either post-partum or in cases of unexplained infertility; medical diagnostic services for gynecological diseases and disorders, namely, for detecting endometriosis by identifying and analyzing biomarkers for diagnostic and/or treatment purposes; medical assessment services, namely, health assessment of a patient's remaining childbearing years based on patient-specific health information.

Medical devices, namely, surgical and nonsurgical devices for treating endometriosis, infertility, and gynecological diseases and disorders.

Medical diagnostic assays for testing for the presence of biomarkers in blood or bodily fluids for diagnosing gynecological diseases, namely endometriosis; Medical diagnostic assays for testing for the presence of biomarkers in uterine tissue for determining a patient's personalized and optimal embryo implantation time and for determining a patient's personalized treatment plan, as well as the composition of microbiome, including presence of normal lactobacillus and targeted pathogenic bacteria, namely, Escherichia, Klebsiella, Enterococcus, Streptococcus, Mycoplasma, Chlamydia, Ureaplasma, Neisseria, Staphylococcus, and Gardnerella; Medical diagnostic assays for testing for the presence of biomarkers in uterine and vaginal tissue for determining a patient's personalized treatment plan; for bacterial, fungal and resistance markers for determining a personalized treatment plan; Medical diagnostic assays for testing for the presence of biomarkers in human biological material for diagnosing gynecological diseases, namely, primary ovarian insufficiency; Pharmaceuticals, namely, therapeutic drugs for treating endometriosis, infertility, and gynecological diseases and disorders

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 21, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 21, 2026 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jul 1, 2026 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jul 1, 2026 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Jun 9, 2026 SUPC
USE AMENDMENT FILED
Mar 2, 2026 IUAF
TEAS STATEMENT OF USE RECEIVED
Mar 2, 2026 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 2, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 8, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jul 8, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 2, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 3, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 2, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 2, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 2, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 8, 2025 GNRN
NON-FINAL ACTION E-MAILED
May 8, 2025 GNRT
NON-FINAL ACTION WRITTEN
May 8, 2025 CNRT
ASSIGNED TO EXAMINER
May 5, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 4, 2025 NWOS
NEW APPLICATION ENTERED
Oct 31, 2024 NWAP